{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tisagenlecleucel",
    "query": {
      "intervention": "tisagenlecleucel"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 28,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tisagenlecleucel&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T19:21:46.155Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03876769",
      "title": "Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B-Cell Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "CTL019",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "1 Year to 25 Years"
      },
      "enrollment_count": 121,
      "start_date": "2019-06-24",
      "completion_date": "2027-10-19",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-08T19:21:46.155Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03876769"
    },
    {
      "nct_id": "NCT02228096",
      "title": "Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B-cell Acute Lymphoblastic Leukemia",
        "Relapsed B-cell Acute Lymphoblastic Leukemia",
        "Refractory B-cell Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "CTL019 T-cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 75,
      "start_date": "2014-08-14",
      "completion_date": "2019-05-24",
      "has_results": true,
      "last_update_posted_date": "2020-11-23",
      "last_synced_at": "2026-09-08T19:21:46.155Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02228096"
    },
    {
      "nct_id": "NCT05199961",
      "title": "Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "interventions": [
        {
          "name": "Digital Health Coaching",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Pack Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 4,
      "start_date": "2022-01-25",
      "completion_date": "2022-09-13",
      "has_results": false,
      "last_update_posted_date": "2023-05-12",
      "last_synced_at": "2026-09-08T19:21:46.155Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05199961"
    },
    {
      "nct_id": "NCT05865301",
      "title": "Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lymphoid Leukemia"
      ],
      "interventions": [
        {
          "name": "Questionnaire for patients receiving therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "Up to 26 Years"
      },
      "enrollment_count": 500,
      "start_date": "2023-06-29",
      "completion_date": "2038-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-09-08T19:21:46.155Z",
      "location_count": 22,
      "location_summary": "Tucson, Arizona • Duarte, California • Palo Alto, California + 19 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Castle",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05865301"
    },
    {
      "nct_id": "NCT03630159",
      "title": "Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Tisagenlecleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-10-09",
      "completion_date": "2021-07-20",
      "has_results": false,
      "last_update_posted_date": "2022-08-15",
      "last_synced_at": "2026-09-08T19:21:46.155Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03630159"
    },
    {
      "nct_id": "NCT07103486",
      "title": "A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 264,
      "start_date": "2021-04-01",
      "completion_date": "2023-01-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-05",
      "last_synced_at": "2026-09-08T19:21:46.155Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07103486"
    },
    {
      "nct_id": "NCT04419909",
      "title": "Retreatment With CTL019/CTL119",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "interventions": [
        {
          "name": "CD19 redirected autologous T cells (CTL019 or CTL119 cells)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2026-05",
      "completion_date": "2026-07-15",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-09-08T19:21:46.155Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04419909"
    },
    {
      "nct_id": "NCT05349201",
      "title": "CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma (DLBCL)",
        "Acute Lymphoblastic Leukemia (ALL)"
      ],
      "interventions": [
        {
          "name": "KYMRIAH",
          "type": "OTHER"
        },
        {
          "name": "YESCARTA",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 273,
      "start_date": "2020-12-09",
      "completion_date": "2021-05-28",
      "has_results": false,
      "last_update_posted_date": "2022-07-01",
      "last_synced_at": "2026-09-08T19:21:46.155Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05349201"
    },
    {
      "nct_id": "NCT03876028",
      "title": "Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Tisagenlecleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2019-06-11",
      "completion_date": "2021-11-01",
      "has_results": false,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-09-08T19:21:46.155Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03876028"
    },
    {
      "nct_id": "NCT07039383",
      "title": "A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 79,
      "start_date": "2023-03-01",
      "completion_date": "2024-06-18",
      "has_results": false,
      "last_update_posted_date": "2025-06-26",
      "last_synced_at": "2026-09-08T19:21:46.155Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07039383"
    }
  ]
}